Education
About Us
Working with TipRanks
Follow Us
BioInvent International AB (SE:BINV)
:BINV
BINV Stock Chart & Stats
kr30.30
kr0.20(0.78%)
At close: 4:00 PM EST
kr30.30
kr0.20(0.78%)
Day’s Range― - ―
52-Week Rangekr22.70 - kr41.60
Previous CloseN/A
Volume47.26K
Average Volume (3M)91.72K
Market Cap
kr1.66B
Enterprise Valuekr1.22B
Total Cash (Recent Filing)kr690.46M
Total Debt (Recent Filing)kr10.69M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.96
Shares Outstanding65,804,360
10 Day Avg. Volume84,851
30 Day Avg. Volume91,723
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)2.86
Price to Sales (P/S)56.69
P/FCF Ratio-6.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt-to-equity provides durable financial flexibility for a development-stage biotech, reducing bankruptcy risk and enabling continued R&D spend or opportunistic partnerships without immediate refinancing pressure over the next 2-6 months.
Very High Gross MarginExtremely high gross margin indicates the company captures strong economics on recognized revenue (collaborations, milestone receipts), supporting scalable profitability if operating leverage improves and clinical programs translate into commercial or recurring partner revenues.
Secured Near-Term Funding RunwayA confirmed cash buffer through Q1 2027 materially reduces near-term dilution risk and supports continued Phase II development and planned readouts, allowing management to advance prioritized assets without immediate capital raises.
Bears Say
Persistent Operating LossesDeep, persistent operating losses reflect ongoing heavy investment in clinical programs and limit internal funding ability. If losses persist, the company may need to raise capital, diluting shareholders and shifting focus from long-term value creation to financing.
Negative Free Cash Flow / Cash BurnSustained negative operating and free cash flow indicate structural cash burn tied to R&D and trials. Even with runway, continued negative FCF implies dependence on external capital or milestone receipts, creating execution and dilution risk over the medium term.
Quarterly Revenue InstabilityVolatile quarter-to-quarter sales driven by fluctuating production revenue and one-off payments undermines predictable cash generation. Reliance on irregular partner payments or milestones complicates planning and increases funding uncertainty beyond the next few quarters.
BioInvent International AB News
BINV FAQ
What was BioInvent International AB’s price range in the past 12 months?
BioInvent International AB lowest stock price was kr22.70 and its highest was kr41.60 in the past 12 months.
What is BioInvent International AB’s market cap?
BioInvent International AB’s market cap is kr1.66B.
When is BioInvent International AB’s upcoming earnings report date?
BioInvent International AB’s upcoming earnings report date is Feb 26, 2026 which is in 7 days.
How were BioInvent International AB’s earnings last quarter?
BioInvent International AB released its earnings results on Oct 29, 2025. The company reported -kr1.964 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.964.
Is BioInvent International AB overvalued?
According to Wall Street analysts BioInvent International AB’s price is currently Overvalued.
Does BioInvent International AB pay dividends?
BioInvent International AB does not currently pay dividends.
What is BioInvent International AB’s EPS estimate?
BioInvent International AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioInvent International AB have?
BioInvent International AB has 65,804,360 shares outstanding.
What happened to BioInvent International AB’s price movement after its last earnings report?
BioInvent International AB reported an EPS of -kr1.964 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 13.919%.
Which hedge fund is a major shareholder of BioInvent International AB?
Currently, no hedge funds are holding shares in SE:BINV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
BINV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call showcased BioInvent's strategic focus on its lead programs, resulting in positive clinical outcomes and increased sales for the nine-month period. However, the quarter saw decreased sales and increased operating costs, leading to negative financial results.View all SE:BINV earnings summariesTechnical Analysis
Hansa Biopharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---